HGHaley Gula

Haley Gula

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haley Gula has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Dominique Missiakas

    Department of Microbiology, Howard Taylor Ricketts Laboratory, The University of Chicago, Lemont, Illinois, USA

    2 shared publications
  • Olaf Schneewind

    Department of Microbiology, Howard Taylor Ricketts Laboratory, The University of Chicago, Lemont, IL 60439

    2 shared publications
  • Adil Mohamed

    Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA

    1 shared publication
  • Alice Chateau

    Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Lemont, Illinois, USA

    1 shared publication
  • Anastasia Tomatsidou

    The University of Chicago, Department of Microbiology, Howard Taylor Ricketts Laboratory, Lemont, IL, USA

    1 shared publication
  • Andrea Valdespino

    Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA

    1 shared publication

Latest Publications

  • Open Access

    Immunoglobulin G subclasses confer protection against Staphylococcus aureus bloodstream dissemination through distinct mechanisms in mouse models

    by Xinhai Chen, Haley Gula, Tonu Pius, Chong Ou, Margaryta Gomozkova, Lai-Xi Wang, Olaf Schneewind, Dominique Missiakas

    Antibodies bind target molecules with exquisite specificity. The removal of these targets is mediated by the effector functions of antibodies. We reported earlier that the monoclonal antibody (mAb) 3F6 promotes opsonophagocytic killing of Staphylococcus aureus in blood and reduces bacterial replication in animals. Here, we generated mouse immunoglobulin G (mIgG) subclass variants and observed a hierarchy in protective efficacy 3F6-mIgG2a > 3F6-mIgG1 ≥ 3F6-mIgG2b >> 3F6-mIgG3 following bloodstream challenge of C57BL/6J mice. This hierarchy was not observed in BALB/cJ mice: All IgG subclasses conferred similar protection. IgG subclasses differ in their ability to activate complement and interact with Fcγ receptors (FcγR) on immune cells. 3F6-mIgG2a-dependent protection was lost in FcγR-deficient, but not in complement-deficient C57BL/6J animals. Measurements of the relative ratio of FcγRIV over complement receptor 3 (CR3) on neutrophils suggest the preferential expression of FcγRIV in C57BL/6 mice and of CR3 in BALB/cJ mice. To determine the physiological significance of these differing ratios, blocking antibodies against FcγRIV or CR3 were administered to animals before challenge. Correlating with the relative abundance of each receptor, 3F6-mIgG2a-dependent protection in C57BL/6J mice showed a greater reliance for FcγRIV while protection in BALB/cJ mice was only impaired upon neutralization of CR3. Thus, 3F6-based clearance of S. aureus in mice relies on a strain-specific contribution of variable FcγR- and complement-dependent pathways. We surmise that these variabilities are the result of genetic polymorphism(s) that may be encountered in other mammals including humans and may have clinical implications in predicting the efficacy of mAb-based therapies.


  • Modeling gastrointestinal anthrax disease

    by So Young Oh, Alice Château, Anastasia Tomatsidou, Derek Elli, Haley Gula, Olaf Schneewind, Dominique Missiakas


  • Top Cited Papers
    Open Access

    Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses

    by Long Chi Nguyen, Dongbo Yang, Vlad Nicolaescu, Thomas J. Best, Haley Gula, Divyasha Saxena, Jon D. Gabbard, Shao-Nong Chen, Takashi Ohtsuki, John Brent Friesen, et al.

    The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.